Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
about
Ribosomopathies: how a common root can cause a tree of pathologiesProgress towards mechanism-based treatment for Diamond-Blackfan anemiaZFP36L2 is required for self-renewal of early burst-forming unit erythroid progenitorsDelayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndromeTreatment of Severe Refractory Hematuria due to Radiation-Induced Hemorrhagic Cystitis with Dexamethasone.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders.Marrow failure: a window into ribosome biologyEarly exposure of murine embryonic stem cells to hematopoietic cytokines differentially directs definitive erythropoiesis and cardiomyogenesis in alginate hydrogel three-dimensional cultures.Ribosomopathies: mechanisms of disease.Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesEstablishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo.Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera.TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond-Blackfan anaemia.Recent insights into inherited bone marrow failure syndromes.Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesFrom stem cells to red blood cells: how far away from the clinical application?Characterization, regulation, and targeting of erythroid progenitors in normal and disordered human erythropoiesis.Regulation of blood volume in lowlanders exposed to high altitude.Using induced human pluripotent stem cells to study Diamond-Blackfan anemia: an outlook on the clinical possibilities.Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis.Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitorsFGFR2 mutations in bent bone dysplasia syndrome activate nucleolar stress and perturb cell fate determination.Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.Revealing nascent proteomics in signaling pathways and cell differentiation.
P2860
Q26781845-E1F4B3CE-AD96-497E-901F-0F12AFAF02C9Q26823710-F1B2F45A-4269-48C5-AC51-07E8B9E8D080Q28508201-17F09B5C-A310-4BBC-95AA-9AFDC43F01FEQ28831412-445A24AA-8B95-4A1D-A3CC-4F374EA0CF3AQ33872715-8EF91883-7B5A-4663-93A1-42E0B022F7FAQ34342944-02668FE1-D3D7-40B5-9A0C-DC1BADFFBE1DQ34358020-A044F226-9A86-47E0-BA0D-27E988889FB4Q34431422-F77D9167-9BE9-4AFB-95F1-2F1BCD5FBBDFQ34437258-84EFD8E4-BD63-4830-A81E-BBB6355D9F87Q34454066-63255814-CA01-49F0-AFE0-CE1E29DB86E1Q34627728-8A5A5B53-B8DD-4EAC-A592-E86BFB5E35BAQ34783754-35E20139-5945-4434-94B4-3D44664EAE83Q35869411-46434F57-6973-4956-9A15-D4AEF166D6ADQ36249436-07991240-F996-48E0-8647-D97D3A62E1A8Q36779451-7E05F5EC-D5F2-4AB5-99DF-65B9ADCDA98BQ37166443-3CC36C87-477A-4181-8260-71E10B364876Q37218274-81406759-DB27-48BD-8558-72688EA56725Q37238278-95A1D3FF-DA52-4601-BE62-2760F837C4D3Q37589103-49196DE7-96BC-4EAC-836E-20AC2C750BE7Q38047020-3C16F7C2-743D-4744-B8FA-0EC84523E296Q38135713-FB6BCFE9-FC22-499B-8CD7-D364563A0202Q38211827-61F2A78B-C954-4539-9FBC-775AA0D57498Q39093732-952A55F6-2A76-4D8E-9A44-42F76E22AFB7Q39345054-B9BEDB3C-B542-4929-A061-2EECB7D664ACQ39873476-B89156FC-F9AD-4464-8F0B-B5A10FE08D17Q40125324-F7D7E79C-F23F-40DE-A473-2EFF3B75D7A6Q40343635-421A8623-001D-4FBB-A342-67A41AE39E83Q43441639-E3A67D7C-3FE7-4D9F-89ED-4A32EB85B6DCQ50280245-6FF944EE-5004-4F1D-B3FF-D9ACAE4BBF29Q51656403-D5317C85-D9A6-4657-8377-D9C16F200A52Q52731168-0718E97C-F1D4-4AE3-A2A4-D859C6EA9DA6
P2860
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
@ast
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
@en
type
label
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
@ast
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
@en
prefLabel
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
@ast
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
@en
P2093
P2860
P1433
P1476
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
@en
P2093
Anupama Narla
Benjamin L Ebert
Donna Neuberg
Fatima Al-Shahrour
J Randall McAuley
Marie McConkey
Shilpee Dutt
Slater Hurst
P2860
P304
P356
10.1182/BLOOD-2010-11-318543
P407
P577
2011-04-28T00:00:00Z